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Normal ageing is characterized by cognitive decline across a range of neurological
functions, which are further impaired in Alzheimer’s disease (AD). Recently, alterations
in zinc (Zn) concentrations, particularly at the synapse, have emerged as a potential
mechanism underlying the cognitive changes that occur in both ageing and AD. Zn is
now accepted as a potent neuromodulator, affecting a variety of signaling pathways at
the synapse that are critical to normal cognition. While the focus has principally been on
the neuron: Zn interaction, there is a growing literature suggesting that glia may also play
a modulatory role in maintaining both Zn ion homeostasis and the normal function of the
synapse. Indeed, zinc transporters (ZnT’s) have been demonstrated in glial cells where Zn
has also been shown to have a role in signaling. Furthermore, there is increasing evidence
that the pathogenesis of AD critically involves glial cells (such as astrocytes), which have
been reported to contribute to amyloid-beta (Aβ) neurotoxicity. This review discusses the
current evidence supporting a complex interplay of glia, Zn dyshomeostasis and synaptic
function in ageing and AD.
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INTRODUCTION
Ageing is an inevitable biological process wherein physical and
mental capabilities are diminished over time, often resulting from
a variety of factors such as cumulative oxidative stress and altered
cell metabolism. This functional decline then ultimately results
in a loss of synaptic plasticity. Ageing in itself does not require
a treatment per se, but maintaining cognitive function into old
age is a concept many aspire to. Currently, normal ageing is
considered to be associated with an overall decline in cognition
occurring via structural and functional brain changes over a
period of time (Meunier et al., 2014). While we have a strong
understanding of the physical decline that occurs in peripheral
organs and systems (e.g., muscle and bone); the particular molec-
ular and cellular changes that occur within the brain and which
ultimately underlie the progression of normal ageing are yet to
be fully determined. Despite the lack of consensus on the precise
neural alterations that occur, it is clear that there is a fine line
between healthy and pathological ageing.
HEALTHY AGEING VS. ALZHEIMER’S DISEASE
Currently, the mechanisms underlying ageing within the brain
remain poorly understood, and indeed one of the hallmarks of
ageing is its variability (Meunier et al., 2014), with the preser-
vation or loss of cognitive functions differing between individ-
uals. The functional memory decline that does occur, however,
is actually well characterized, with executive functioning, pro-
cessing speed and reasoning ability declining from middle age
(Deary et al., 2009). While the molecular and cellular mechanisms
underlying this are yet to be fully elucidated, it is important to
note the potential intersection with pathological ageing, as seen in
conditions such as Alzheimer’s disease (AD). Ageing is the greatest
risk factor for the development of AD, which is the most common
form of age-related dementia (Mosconi et al., 2010; Reitz et al.,
2011), and it has been suggested that AD may simply be an accel-
eration of the normal ageing process. Indeed, many of the cogni-
tive impairments seen in normal ageing are further exacerbated in
AD. Symptomatically, AD is characterized by marked deficiencies
in episodic memory, attention, perception and speech (Mesulam,
1999) as well as altered mood (Lopez et al., 2001). Pathologically
it is defined by the accumulation of intracellular neurofibrillary
tangles (comprised of abnormally phosphorylated tau protein)
and extracellular plaques (comprised of misfolded forms of the
amyloid-β (Aβ) peptide) within the brain. With regards to the
potential for a mechanistic overlap between ageing and AD, recent
evidence points to zinc (Zn) homeostasis as key player in both
normal and pathological ageing. Specifically, it has been demon-
strated that there is a modulation in brain Zn homeostasis in both
ageing and AD (Religa et al., 2006; Haase and Rink, 2009) that
results in a neuronal Zn deficiency that may ultimately underlie
the onset and progression of cognitive deficits seen in both.
ZINC
Zn; an essential trace element and second in abundance in mam-
malian tissues (Wang et al., 2005; Paoletti et al., 2009), is critical
for immunity, growth and development (Nolte et al., 2004), is
a cofactor for more than 300 enzymes and is essential for the
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correct functioning of over 2000 transcription factors (Takeda,
2000; Levenson and Tassabehji, 2007; Jeong and Eide, 2013). The
brain has the largest Zn content (Vasto et al., 2008), the levels of
which are tightly controlled by three main families of proteins
that have a distinct tissue and cell level pattern of localization
and expression (Hennigar and Kelleher, 2012). These are; the
metallothioneins (MT’s; that also coordinate a variety of other
metal ions), zinc transporters (ZnT’s) and Zn-regulated and iron-
regulated transporter proteins (ZIP’s; recent evidence has also
implicated the presenilin family as capable of influencing Zn
concentrations (Greenough et al., 2013)). Currently there are four
MT isoforms, 10 ZnT’s, 15 ZIP’s and two presenilins. The ZnT’s
coordinate intracellular Zn homeostasis while the ZIP’s primary
function is to regulate Zn uptake (Guerinot, 2000). The role of the
MT’s is to control cytosolic concentrations through the binding
and distribution of Zn (Mocchegiani et al., 2001). A number
of studies have examined the effect of altered MT on brain
metal levels, with mice deficient in both MT-I/II (Manso et al.,
2011) and MT-III (Erickson et al., 1997), for example, shown
to have altered brain Zn levels. Cumulatively, these proteins are
responsible for the influx and efflux of Zn2+ in a variety of
cellular compartments, including vesicles, Golgi apparatus, and
mitochondria (Figure 1).
As Zn is essential for normal brain function, Zn
dyshomeostasis has been linked to a range of neurological
abnormalities including (but not limited to) depression and
schizophrenia (Levenson and Tassabehji, 2007), AD, amyotrophic
lateral sclerosis (ALS), Down’s syndrome, multiple sclerosis
(Grabrucker et al., 2011) and normal age-related cognitive decline
(Adlard et al., 2014). Neurological events such as ischemia,
seizures and traumatic brain injury have also been linked to
altered Zn levels (Nolte et al., 2004; Grabrucker et al., 2011). In
addition to this, excess Zn has been implicated in the processes
that lead to cellular damage through excitotoxicity or oxidative
stress (Morris and Levenson, 2012). This is particularly pertinent
at the synapse where the presence or absence of Zn can be crucial.
ZINC AT THE SYNAPSE (NEURON-NEURON)
Though it is well-known that Zn is tightly bound to
macromolecules in the brain, a small number of Zn ions
(approx. 10–15% total brain Zn) exist as chelatable Zn (Levenson
and Tassabehji, 2007) primarily within synaptic vesicles at
glutamatergic synapses (Paoletti et al., 2009; Sensi et al., 2009;
Karol et al., 2010). During neuronal activation Zn is released into
the synaptic cleft alongside glutamate (Lee et al., 2012) where it
interacts with synaptic receptors, ion channels and transporters
to modulate synaptic activity (Takeda and Tamano, 2012). Most
importantly, this Zn acts on neuronal receptors and voltage-gated
calcium channels (VGCC) to regulate downstream signaling
pathways and neuronal processes such as; normal neuronal firing,
long-term potentiation (LTP) and long-term depression (LTD)
by acting on N-methyl-D-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors,
particularly in the hippocampus. This is further evidenced by
the age-dependent cognitive phenotype recently reported in zinc
transporter 3 (ZnT3) knockout mice (Adlard et al., 2010), which
lack synaptic Zn at the glutamatergic synapse. Interestingly ZnT3
mRNA and protein levels are decreased in AD (Beyer et al., 2009;
Adlard et al., 2010). Research has also demonstrated that Zn is
capable of inducing functional and conformational changes in
NMDA receptors (Sirrieh et al., 2013) and is therefore considered
essential for the modulation of synaptic neurotransmission
(Roberts et al., 2012).
Likewise, Salazar et al. (2005) further demonstrated an
intimate connection between Zn and vesicular glutamate trans-
porter 1 (VGlut1) which is expressed in synaptic terminals
that co-release Zn and glutamate. Glutamate, the major exci-
tatory neurotransmitter in the central nervous system (CNS),
FIGURE 1 | Illustration of the proteins responsible for the homeostasis of Zn. Adapted from Sensi et al. (2009).
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is essential to synaptic plasticity underlying cognition and
memory. Vglut1 and ZnT3 coexist in nerve terminals and
are also co-targeted to the same vesicle population and
are reciprocally regulated; Zn uptake is increased by Vglut1
expression while glutamate uptake is increased by produc-
tion of ZnT3. This becomes exceedingly relevant as evidence
is emerging for a role of astrocytes in Zn homeostasis and
gliotransmission.
ZINC AND ASTROCYTES
Astrocytes have a variety of roles in regulating volume and
composition of extracellular space, forming and controlling the
blood-brain barrier (BBB) and also maintaining the architecture
of gray matter (Kettenmann and Verkhratsky, 2008). Astrocytes
are capable of rapidly accumulating Zn (Nolte et al., 2004) and
they also express a range of ZnT’s including ZIP14 (Bishop
et al., 2010) and ZnT3 (which is intimately involved in cog-
nition) under stress conditions (Sun et al., 2012). It is known
that glial cells in the cerebellum also express ZnT1, ZnT3, ZnT4
and ZnT6 (Wang et al., 2005). The biological implications, and
indeed the cognitive effect, of this Zn accumulation and Zn
transporter expression are currently unknown and remain an
under-researched area. That being said, astrocytes take up glu-
tamate from the synapse and convert it to glutamine which
is subsequently released and retrieved by neurons for conver-
sion back to glutamate and into the main inhibitory transmit-
ter gamma-aminobutyric acid (GABA; Yeh et al., 2013). This
glutamate-glutamine cycle is essential to maintaining glutamater-
gic and GABA-ergic neurotransmission, disruption of which
could cause synaptic dysfunction (Yeh et al., 2013) and cognitive
deficits. Moreover, activation of astrocytic G-protein coupled
receptors stimulates the release of glutamate as well as poten-
tiates NMDA receptor functions (Lee et al., 2007). Thus, the
close association/co-release of Zn and glutamate at the synapse
may, therefore, extend to a role for astrocytes/glia in the synap-
tic regulation of Zn that may be critical for the prevention
of excitotoxicity or various other post-synaptic or cognitive
processes.
Additionally, astrocytes increase intracellular Ca2+ levels in
response to synaptic transmission (Morris et al., 2013). This may
be important in LTP which is induced by high-frequency stim-
ulation causing a sustained increase in transmission that usually
depends on Ca2+ influx through NMDA receptors. A recent study
by Han et al. (2013), which grafted human astrocytes into mice,
showed enhanced LTP and improved performance on cognitive
tests. It should be noted here that oxidative stress (previously
mentioned as a major contributor to cellular damage) is known
to affect metabolic pathways of astrocytes that are important for
the delivery of metabolites to neurons (Theusen et al., 2010). This
demonstrates a common cause of functional disruption across
cell types essential to Zn homeostasis that may be especially
detrimental at the synapse.
TRIPARTITE SYNAPSE
The role of Zn at synapses is particularly germane to both normal
and pathological ageing. Neuroplasticity deteriorates in normal
ageing and loss of synapses is a key indicator and currently the
best correlate of cognitive decline in AD (Takahashi et al., 2010).
However, the current study of synapses falls well-short of that
necessary to fully comprehend the complex processes that occur.
The model of a synapse over the past decades of research has been
that of neuron-neuron electrical impulses, but recent advances
in both scientific thinking and techniques has brought us to a
more accurate representation. Currently the most accepted model
is that of the “tripartite” synapse where the pre- and post-synaptic
neuron terminals are physically enveloped by astrocytic processes
which actively participate in synaptic neurotransmission. These
astrocytic processes release a variety of neuroactive molecules
including adenosine, GABA, prostaglandins and ATP which can
influence both neuronal and synaptic physiology (Volterra and
Bezzi, 2002).
Though the link has previously not been made, the evidence
presented here suggests that there may be an interaction between
neurons, astrocytes, Zn and glutamate that is critical to normal
synaptic health and function, potentially affecting neurotrans-
mission and other cellular cascades involved in cognition, as
discussed earlier. This is an area of research that clearly needs
further investigation, as the diminished learning and memory
abilities seen in ageing may be caused by a failure in neuron-
glia communications at the synapse that disrupts Zn homeostasis
to result in downstream modifications to, among other things,
synaptic ion channels.
MICROGLIA AT THE SYNAPSE
In addition to the role of astrocytes at the synapse, recent stud-
ies investigating microglia suggest this tripartite system may be
just as constraining to synaptic research as the previous model.
Currently, the literature is dominated by what is thought to be
the primary function of microglia; surveying the environment
for damage and protecting neural material (Stollg and Jander,
1999). Resting microglia have small cell bodies and elongated
processes, in response to a traumatic or pathogenic event they
alter their morphology, withdraw their processes and become
globular. These activated microglia are able to migrate to the
damage site, phagocytose any cellular debris and release vari-
ous neuroactive compounds (Wake et al., 2009). However, it is
almost certain that microglia have a much larger role in normal
brain function and cognition than previously thought. Resting
microglia have been shown to be highly dynamic, extending
and retracting processes with brief static periods, apparently at
random (Nimmerjahn et al., 2005). Microglia express most of
the major classes and subtypes of both excitatory and inhibitory
neurotransmitter receptors and ion channels which have classi-
cally been found at neuronal synapses, though little is known
about their role in inactivated microglia. Indeed, research by
Wake et al. (2009) showed microglial processes making direct
transient contact with synapses. Moreover, microglia appear to
contact neighboring astrocytes, neuronal cell bodies and blood
vessels (Morris et al., 2013). These findings have vast impli-
cations for our current understanding of both synaptic and
cognitive functioning in that such findings require scientists
to completely alter their perceptions and re-consider the cur-
rent models of synapses as well as the dominant focus on
neurons throughout past and present research and literature.
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 137 | 3
Hancock et al. Glia and zinc in ageing and Alzheimer’s disease
Figure 2 illustrates the potential structure of this new synaptic
model.
Microglia also release cytokines, which have central
physiological roles in synaptic plasticity, neurogenesis and
learning and memory in the normal brain (Morris et al., 2013)
possibly through their influence on MT expression and hence
Zn concentration (Vasto et al., 2008). Microglia may, however,
have a more direct role in Zn homeostasis as Higashi et al. (2011)
recently learned. Microglia can directly uptake Zn via ZIP1,
which is also a trigger for sequential microglial activation. In a
study by Knoch et al. (2008) the release of intraneuronal Zn2+
and a subsequent increase in neuronal voltage-gated K+ currents
as caused by the release of ROS from activated microglia lead
to neuronal cell death. This suggests the primary mechanism of
neuronal apoptosis may in fact, be the earlier damage to glial cells.
This is accordance with findings by Kaindl et al. (2008, 2012) that
activation of microglial NMDA receptors results in an increase in
oxidative stress in vitro (Kaindl et al., 2008, 2012). Glial senescence
during ageing can also impact normal synapse function (Wong,
2013) and result in aberrant connectivity between neurons.
ZINC, GLIA AND PATHOLOGICAL AGEING
Both Zn and glia appear to have multifarious roles within
the brain, especially within synapses. Indeed, synaptic loss is the
fundamental feature of the ageing brain that links neuropathology
to cognitive decline in AD (Talantova et al., 2013). This is largely
applicable to pathological ageing and neurodegenerative disorders
such as AD wherein the abnormal deposition of misfolded Aβ
peptide into plaques, which bind Zn, results in a significant
FIGURE 2 | Proposed glutamatergic synapse structure. Including
astrocytes and microglia.
decrease in intracellular Zn (Bush et al., 1994). Moreover, the
plaques are in abundance in brain areas with high densities of
FIGURE 3 | Neuron-glia and zinc synaptic interactions in (A) normal, (B)
aged, and (C) Alzheimer’s disease.
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glutamatergic synapses such as the hippocampus, exhibiting a
similar distribution to that of Zn with glutamatergic neurons.
Additionally, microglia have been suggested to play a role in
plaque formation (Stollg and Jander, 1999). Further research
by Desphande et al. (2009) clearly demonstrated oligomers of
Aβ interfering with synaptic function, suggesting that Zn at the
NMDA receptor attracts the Aβ in addition to its high binding
affinity to synapses. Keeping the aforementioned information
in mind, it is reasonable to suggest that AD may be the result
of synaptic dysfunction caused by a disruption of the fine and
complex interplay between Zn, neuronal, glial and microglial
communication that occurs within the synapse. Due to the high
binding affinity of Aβ to both Zn and synapses, upon activation
of the pre-synaptic neuron and the subsequent release of Zn into
the synapse, the Zn can be captured by the Aβ and lodged within
the plaque to ultimately disrupt synaptic transmission. A decrease
in available Zn for neurotransmission and calcium signaling then
causes downstream errors that may result in further Zn dyshome-
ostasis in a negative feedback loop eventually leading to glial
damage and apoptosis through microglial activation. Disruption
of cytokine signaling and failure of the signaling mechanisms
maintaining the phenotype of microglia in the normal brain may
contribute to learning and memory dysfunction and synaptic
pathologies such as AD or dementia which, in some of its
forms, is at its onset a result of a failure to maintain microglia
in their ramified state (Morris et al., 2013). A diagrammatic
representation of the change in Zn2+ in the progression from
normal to pathological ageing is illustrated in Figure 3.
CONCLUSION
Herein evidence supporting a link between Zn, glia and cognitive
decline has been presented and discussed. The research thus
far suggests the possibility of a feedback loop between Zn
homeostasis, synaptic excitation, neurons, astrocytes and
microglia. Perhaps the most appropriate definition is that of
Morris et al. (2013) that a synapse is “a complex, dynamic and
often transient structure involving several cells interacting with a
sophisticated extracellular matrix and milieu”. The contribution
of microglia and astrocytes to synaptic plasticity mechanisms
relevant to learning and memory must be included in studies.
Only by including these cell types in future research will we
come to truly understand the intricate molecular mechanisms
underlying the ageing processes; thereby discovering potential
avenues for intervention to ensure that we are able to enjoy our
twilight years to the best of our cognitive ability.
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